Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.39 |
| ▸ | AHR | P35869 | 3/20 | 0.63 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.63 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.63 |
| ▸ | ITGAL | P20701 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | ADK | P55263 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL16757657 | 0.92 | AHR (0.53) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL31206792 | 0.87 | TRPA1 (0.61) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL5174731 | 0.87 | TRPA1 (0.61) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL28976104 | 0.87 | TRPA1 (0.52) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL28479409 | 0.86 | TRPA1 (0.77) | AHRTRPA1CA1CA2ITGB2 | |
| Mandelic Acid SCHEMBL29138545 | 0.84 | LMNA (0.60) | AHRTRPA1CA1CA2ITGB2 | |
| Mandelic Acid SCHEMBL30669700 | 0.84 | LMNA (0.60) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL28131517 | 0.84 | TRPA1 (0.74) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL2704553 | 0.84 | TRPA1 (0.74) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL28131513 | 0.84 | TRPA1 (0.74) | AHRTRPA1CA1CA2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452149-A | Preparation method, dihydroindole compounds and the purposes of dihydroindole compounds | BEIJING XINKAIYUAN PHARMACEUTICALS CO LTD | 2019-11-15 | — | — | CN | claimed |
| US-11918984-B2 | Annulation catalysts via direct C—H bond amination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220016613-A1 | NOVEL ANNULATION CATALYSTS VIA DIRECT C-H BOND AMINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-01-20 | — | — | US | disclosed |
| WO-2020061300-A1 | NOVEL ANNULATION CATALYSTS VIA DIRECT C-H BOND AMINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-26 | — | — | WO | disclosed |
| CN-110452149-A | Preparation method, dihydroindole compounds and the purposes of dihydroindole compounds | BEIJING XINKAIYUAN PHARMACEUTICALS CO LTD | 2019-11-15 | — | — | CN | disclosed |
| CN-102227431-A | Indole and indoline derivatives and methods of use thereof | ABBOTT LAB | 2011-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918984-B2 | Annulation catalysts via direct C—H bond amination | AADAC, AOC1, CAD | SLC6A2 3540/4885SLC6A3 2395/4885AHR 63/4885 |
| US-20220016613-A1 | NOVEL ANNULATION CATALYSTS VIA DIRECT C-H BOND AMINATION | AADAC, CAD, AOC1 | SLC6A2 3657/4885SLC6A3 2254/4885AHR 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.